Sulfoglucuronosyl glycolipids as putative antigens for autoimmune inner ear disease

M. Yamawaki, T. Ariga, Y. Gao, A. Tokuda, J. S. Yu, A. Sismanis, R. K. Yu

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Autoimmune inner ear disease is diagnosed based on clinical history of fluctuating but progressive sensorineural hearing loss (SNHL) with or without vestibular symptoms occurring over weeks to months. An initial response to steroids or immunosuppressive drugs usually reverses the hearing loss. In search of specific diagnostic and therapeutic markers for autoimmune inner ear diseases, we investigated serum anti-glycolipid antibody activities in these patients by two different methods, HPTLC-immunoblotting and ELISA. We found that 37 out of 74 patients of clinically diagnosed autoimmune inner ear disease (30 of sensorineural hearing loss (SNHL) (group I), 14 of vestibular symptoms only (group II), 30 of Menieres symptoms (with both hearing loss and vestibular symptoms) (group III)) showed positive anti-sulfoglucuronosyl lactosaminyl paragloboside (SGLPG) antibody titers (p <0.001). On the other hand, anti-sulfoglucuronosyl paragloboside (SGPG) titers were not elevated in these conditions. In contrast, only 3 out of 56 pathological control and 2 out of 28 healthy volunteers had measurable anti-SGLPG antibody titers. We further analyzed the localization of SGLPG in the auditory pathway and found that the antigens existed exclusively in inner ear and the eighth nerve, but not in pons, cerebellum, nor cerebrum. We conclude that the anti-SGLPG antibody represents a novel diagnostic marker for autoimmune inner ear disease and may participate in the pathogenesis of this disease.

Original languageEnglish (US)
Pages (from-to)111-116
Number of pages6
JournalJournal of Neuroimmunology
Volume84
Issue number2
DOIs
StatePublished - Apr 15 1998

Fingerprint

Labyrinth Diseases
Glycolipids
Antigens
Sensorineural Hearing Loss
Hearing Loss
Antibodies
Auditory Pathways
Pons
Cerebrum
Inner Ear
Immunosuppressive Agents
Immunoblotting
Cerebellum
Anti-Idiotypic Antibodies
Healthy Volunteers
Enzyme-Linked Immunosorbent Assay
Steroids
sulfate-3-glucuronyl paragloboside
Serum
Pharmaceutical Preparations

Keywords

  • Anti-SGLPG antibodies
  • Autoimmune inner ear disease
  • Sensorineural hearing loss
  • Sulfoglucuronosyl glycolipids (SGGLs)
  • Sulfoglucuronosyl lactosaminyl paragloboside (SGLPG)
  • Sulfoglucuronosyl paragloboside (SGPG)

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Neurology
  • Clinical Neurology

Cite this

Sulfoglucuronosyl glycolipids as putative antigens for autoimmune inner ear disease. / Yamawaki, M.; Ariga, T.; Gao, Y.; Tokuda, A.; Yu, J. S.; Sismanis, A.; Yu, R. K.

In: Journal of Neuroimmunology, Vol. 84, No. 2, 15.04.1998, p. 111-116.

Research output: Contribution to journalArticle

Yamawaki, M. ; Ariga, T. ; Gao, Y. ; Tokuda, A. ; Yu, J. S. ; Sismanis, A. ; Yu, R. K. / Sulfoglucuronosyl glycolipids as putative antigens for autoimmune inner ear disease. In: Journal of Neuroimmunology. 1998 ; Vol. 84, No. 2. pp. 111-116.
@article{f1f0e34fb4b4498abb005f8cf07d6b3c,
title = "Sulfoglucuronosyl glycolipids as putative antigens for autoimmune inner ear disease",
abstract = "Autoimmune inner ear disease is diagnosed based on clinical history of fluctuating but progressive sensorineural hearing loss (SNHL) with or without vestibular symptoms occurring over weeks to months. An initial response to steroids or immunosuppressive drugs usually reverses the hearing loss. In search of specific diagnostic and therapeutic markers for autoimmune inner ear diseases, we investigated serum anti-glycolipid antibody activities in these patients by two different methods, HPTLC-immunoblotting and ELISA. We found that 37 out of 74 patients of clinically diagnosed autoimmune inner ear disease (30 of sensorineural hearing loss (SNHL) (group I), 14 of vestibular symptoms only (group II), 30 of Menieres symptoms (with both hearing loss and vestibular symptoms) (group III)) showed positive anti-sulfoglucuronosyl lactosaminyl paragloboside (SGLPG) antibody titers (p <0.001). On the other hand, anti-sulfoglucuronosyl paragloboside (SGPG) titers were not elevated in these conditions. In contrast, only 3 out of 56 pathological control and 2 out of 28 healthy volunteers had measurable anti-SGLPG antibody titers. We further analyzed the localization of SGLPG in the auditory pathway and found that the antigens existed exclusively in inner ear and the eighth nerve, but not in pons, cerebellum, nor cerebrum. We conclude that the anti-SGLPG antibody represents a novel diagnostic marker for autoimmune inner ear disease and may participate in the pathogenesis of this disease.",
keywords = "Anti-SGLPG antibodies, Autoimmune inner ear disease, Sensorineural hearing loss, Sulfoglucuronosyl glycolipids (SGGLs), Sulfoglucuronosyl lactosaminyl paragloboside (SGLPG), Sulfoglucuronosyl paragloboside (SGPG)",
author = "M. Yamawaki and T. Ariga and Y. Gao and A. Tokuda and Yu, {J. S.} and A. Sismanis and Yu, {R. K.}",
year = "1998",
month = "4",
day = "15",
doi = "10.1016/S0165-5728(97)00210-5",
language = "English (US)",
volume = "84",
pages = "111--116",
journal = "Journal of Neuroimmunology",
issn = "0165-5728",
publisher = "Elsevier",
number = "2",

}

TY - JOUR

T1 - Sulfoglucuronosyl glycolipids as putative antigens for autoimmune inner ear disease

AU - Yamawaki, M.

AU - Ariga, T.

AU - Gao, Y.

AU - Tokuda, A.

AU - Yu, J. S.

AU - Sismanis, A.

AU - Yu, R. K.

PY - 1998/4/15

Y1 - 1998/4/15

N2 - Autoimmune inner ear disease is diagnosed based on clinical history of fluctuating but progressive sensorineural hearing loss (SNHL) with or without vestibular symptoms occurring over weeks to months. An initial response to steroids or immunosuppressive drugs usually reverses the hearing loss. In search of specific diagnostic and therapeutic markers for autoimmune inner ear diseases, we investigated serum anti-glycolipid antibody activities in these patients by two different methods, HPTLC-immunoblotting and ELISA. We found that 37 out of 74 patients of clinically diagnosed autoimmune inner ear disease (30 of sensorineural hearing loss (SNHL) (group I), 14 of vestibular symptoms only (group II), 30 of Menieres symptoms (with both hearing loss and vestibular symptoms) (group III)) showed positive anti-sulfoglucuronosyl lactosaminyl paragloboside (SGLPG) antibody titers (p <0.001). On the other hand, anti-sulfoglucuronosyl paragloboside (SGPG) titers were not elevated in these conditions. In contrast, only 3 out of 56 pathological control and 2 out of 28 healthy volunteers had measurable anti-SGLPG antibody titers. We further analyzed the localization of SGLPG in the auditory pathway and found that the antigens existed exclusively in inner ear and the eighth nerve, but not in pons, cerebellum, nor cerebrum. We conclude that the anti-SGLPG antibody represents a novel diagnostic marker for autoimmune inner ear disease and may participate in the pathogenesis of this disease.

AB - Autoimmune inner ear disease is diagnosed based on clinical history of fluctuating but progressive sensorineural hearing loss (SNHL) with or without vestibular symptoms occurring over weeks to months. An initial response to steroids or immunosuppressive drugs usually reverses the hearing loss. In search of specific diagnostic and therapeutic markers for autoimmune inner ear diseases, we investigated serum anti-glycolipid antibody activities in these patients by two different methods, HPTLC-immunoblotting and ELISA. We found that 37 out of 74 patients of clinically diagnosed autoimmune inner ear disease (30 of sensorineural hearing loss (SNHL) (group I), 14 of vestibular symptoms only (group II), 30 of Menieres symptoms (with both hearing loss and vestibular symptoms) (group III)) showed positive anti-sulfoglucuronosyl lactosaminyl paragloboside (SGLPG) antibody titers (p <0.001). On the other hand, anti-sulfoglucuronosyl paragloboside (SGPG) titers were not elevated in these conditions. In contrast, only 3 out of 56 pathological control and 2 out of 28 healthy volunteers had measurable anti-SGLPG antibody titers. We further analyzed the localization of SGLPG in the auditory pathway and found that the antigens existed exclusively in inner ear and the eighth nerve, but not in pons, cerebellum, nor cerebrum. We conclude that the anti-SGLPG antibody represents a novel diagnostic marker for autoimmune inner ear disease and may participate in the pathogenesis of this disease.

KW - Anti-SGLPG antibodies

KW - Autoimmune inner ear disease

KW - Sensorineural hearing loss

KW - Sulfoglucuronosyl glycolipids (SGGLs)

KW - Sulfoglucuronosyl lactosaminyl paragloboside (SGLPG)

KW - Sulfoglucuronosyl paragloboside (SGPG)

UR - http://www.scopus.com/inward/record.url?scp=0032522206&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032522206&partnerID=8YFLogxK

U2 - 10.1016/S0165-5728(97)00210-5

DO - 10.1016/S0165-5728(97)00210-5

M3 - Article

C2 - 9628451

AN - SCOPUS:0032522206

VL - 84

SP - 111

EP - 116

JO - Journal of Neuroimmunology

JF - Journal of Neuroimmunology

SN - 0165-5728

IS - 2

ER -